Protective effect of captopril and enaraprilat, angiotensin-converting enzyme inhibitors, on para-nonylphenol-induced {radical dot}OH generation and dopamine efflux in rat striatum

Toxicology

Volumn 250, Issue 2-3, 2008, Pages 96-99

  Obata, Toshio ^a   Takahashi, Shigehiro ^a   Kashiwagi, Yoshitomo ^a   Kubota, Shunichiro ^b  

^a OHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

1 Methyl 4 phenylpyridinium ion (MPP+); Angiotensin converting enzyme inhibitor; Dopamine; Hydroxyl radical; para Nonylphenol; Striatum

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 4 NONYLPHENOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ENALAPRILAT; HYDROXYL RADICAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; BRAIN TOXICITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

1-METHYL-4-PHENYLPYRIDINIUM; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; CATECHOLS; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRILAT; HYDROXYL RADICAL; IRON; MALE; NEOSTRIATUM; PHENOLS; RATS; RATS, WISTAR;

RATTUS;

EID: 49849104484     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.06.005     Document Type: Article

References (23)

1. Bagchi B., Prasad R., and Das D.K. Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor. Biochem. Biophys. Res. Commun. 158 (1989) 52-57
2. Brown D.C., Steward L.J., Ge J., and Barnes N.M. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br. J. Pharmacol. 118 (1996) 414-420
3. Chai S.Y., Mendelsohn F.A., and Paxinos G. Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography. Neuroscience 20 (1987) 615-627
4. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120 (1984) 574-578
5. Chiueh C.C., Miyake H., and Peng M.T. Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism. Adv. Neurol. 60 (1993) 251-258
6. Fernandes A.C., Filipe P.M., Freitas J.P., and Manso C.F. Different effects of thiol and nonthiol ace inhibitors on copper-induced lipid and protein oxidative modification. Free Rad. Biol. Med. 20 (1996) 507-514
7. Floyd R.A., Watson J.J., and Wong P.K. Sensitive assay of hydroxyl free radical formation utilizing high pressure liquid chromatography with electrochemical detection of phenol and salicylate hydroxylation products. J. Biochem. Biophys. Methods 10 (1984) 221-235
8. Halliwell B., Kaur H., and Ingleman-Sundberg I.M. Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Rad. Biol. Med. 10 (1991) 439-441
9. Hirsch E., Graybiel A.M., and Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
10. Jenkins T.A., Allen A.M., Chai S.Y., MacGregor D.P., Paxinos G., and Mendelsohn F.A. Interactions of angiotensin II with central dopamine. Adv. Exp. Med. Biol. 396 (1996) 93-103
11. Jenkins T.A., Mendelsohn F.A.O., and Chai S.Y. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J. Neurochem. 68 (1997) 1304-1311
12. Jenkins T.A., Wong J.Y., Howells D.W., Mendelsohn F.A., and Chai S.Y. Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in the MPTP-treated mouse. J. Neurochem. 73 (1999) 214-219
13. Konings C.H., Kuiper M.A., Bergmans P.L., Grijpma A.M., van Kamp G.J., and Wolters E.C. Increased angiotensin converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease. Clin. Chim. Acta 231 (1994) 101-106
14. Mak I.T., Freedman A.M., Dickens B.F., and Weglicki W.B. Protective effects of sulfhydryl containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol. 40 (1990) 2169-2175
15. Markey S.P., and Schmuff N.R. The pharmacology of the Parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine) and structurally related compounds. Med. Res. Rev. 6 (1986) 389-429
16. Obata T. Protective effect of imidaprilat, a new angiotensin-converting enzyme inhibitor against 1-methyl-4-phenylpyridinium ion-induced {radical dot}OH generation in rat striatum. Eur. J. Pharmacol. 378 (1999) 39-45
17. Obata T., Hosokawa H., and Yamanaka Y. In vivo monitoring of norepinephrine and {radical dot}OH generation on myocardial ischemic injury by dialysis technique. Am. J. Physiol. 266 (1994) H903-H908
18. Obata T., and Kubota S. Formation of hydroxy radicals by environmental estrogen-like chemicals in rat striatum. Neurosci. Lett. 296 (2000) 41-44
19. Obata T., and Yamanaka Y. Protective effect of imidaprilat, an angiotensin-converting enzyme inhibitor on {radical dot}OH generation in rat myocardium. Biochim. Biophys. Acta 1472 (1999) 62-70
20. Paxinos G., and Watson C. The Rat Brain Stereotaxic Coordinates. 2nd ed. (1982), Academic Press, Sydney
21. Poth M.M., Heath R.G., and Ward M. Angiotensin-converting enzyme in human brain. J. Neurochem. 25 (1975) 83-85
22. Youdim M.B.H., Ben-Shachar D., and Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol. Scand. 126 (1989) 47-54
23. Zubenko G.S., Volicer L., Direnfeld L.K., Freeman M., Langlais P.J., and Nixon R.A. Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy. Brain Res. 328 (1985) 215-221